Impact Factor
3.18
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
2.18
388 total citations
h5-index
25
h5 depth signal
Cited share
71.2%
136 of 191
Total citations
388
Citation footprint
Metric signal
2.11
External metric anchor
Self-citation
1.3%
5 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
China
864
United States
117
Italy
114
Japan
59
Turkey
58
Citing Fields of Research
Oncology
407
Lung Cancer
275
Cancer, Autophagy & Apoptosis
268
Noncoding RNA
213
Cancer & Development
191
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
5,032
Articles tracked across the journal lifetime
Indexed publication set
191
136 cited publications
Last 12 months
77
6.4 publications/month
Open access share
23.4%
18 OA publications in the last year
Leading citing country
China
864 citing publications
Leading citing field
Oncology
407 citing publications
Latest tracked publication
7 October 2026
10 recent records available
Coverage & Indexing History
v1n1,Oct. 1990-
v1n1,Oct. 1990-
Active Coverage
Research Focus & Classification
Indexed Subjects
Lung Cancer
Oncology
Cancer, Autophagy & Apoptosis
Immunology
Breast Cancer
Liver & Colon Cancer
Broad Categories
Antineoplastic Agents
Lung Cancer
Cancer, Autophagy & Apoptosis
Immunology
Cancer & Development
Hematology
MeSH Descriptors
Antineoplastic Agents
Neoplasms
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1097/cad.0000000000001849
Open DOI
Publishing with Anti-Cancer Drugs: what authors should know
02
DOI 10.1097/cad.0000000000001847
Open DOI
Primary resistant disease is clinically heterogeneous in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
The study aimed to characterize clinical heterogeneity among patients with primary resistant disease (PRD) after first-line nivolumab plus ipilimumab (NIVO+IPI) for metastatic renal cell carcinoma (mRCC) and to explore clinical factors a...
03
DOI 10.1097/cad.0000000000001848
Open DOI
Macrophage-associated epithelial–mesenchymal transition in human breast cancer: contextualizing innate immune sensing programs
To determine whether innate immune-sensing activity is associated with epithelial–mesenchymal transition (EMT) and related tumor-aggressiveness programs in human breast cancer. We analyzed RNA sequencing and clinical data from The Cancer...
04
DOI 10.1097/cad.0000000000001846
Open DOI
Pathologic complete response after first-line tislelizumab, cetuximab, and dabrafenib in microsatellite-stable BRAF V600E-mutant metastatic colorectal cancer: a case report
BRAF V600E-mutant metastatic colorectal cancer (mCRC) is characterized by aggressive disease behavior and limited responsiveness to conventional systemic therapy. Although BRAF/EGFR -targeted therapies have improved clinical outcomes, du...
05
DOI 10.1097/cad.0000000000001843
Open DOI
A global perspective in anti-cancer drugs
Was not provided for this article.
06
DOI 10.1097/cad.0000000000001844
Open DOI
Anlotinib inhibits glioma cell proliferation, migration, and invasion by suppressing c-MET/AKT/mTOR signaling and altering autophagy-associated protein expression
Glioma remains difficult to treat because malignant cells show rapid proliferation, diffuse invasion, and frequent recurrence. This study investigated the direct antitumor effects of anlotinib in human glioma cells and examined whether t...
07
DOI 10.1097/cad.0000000000001842
Open DOI
Prophylactic tramadol for oxaliplatin-induced peripheral vascular pain: a single-arm retrospective study
Oxaliplatin-induced peripheral vascular pain (OIVP) often requires central venous port placement. Conventional preventive strategies have limited efficacy, and the use of some effective analgesics is restricted. This single-center retros...
08
DOI 10.1097/cad.0000000000001840
Open DOI
Estrogen-related receptor α promotes breast cancer cell migration and invasion by activating transforming growth factor β signaling
Breast cancer is a major cause of cancer-related mortality among women, and many patients eventually experience recurrence and progression to metastasis, despite advances in treatment. Estrogen-related receptor α (ERRα), an orphan nuclea...
09
DOI 10.1097/cad.0000000000001838
Open DOI
MLN4924 suppresses pancreatic cancer progression and enhances chemosensitivity to gemcitabine by targeting the PTGS2/EGFR–PI3K/Akt/mTOR signaling axis
Pancreatic cancer is a highly lethal digestive malignancy characterized by insidious onset and rapid progression. Approximately 80% of patients are diagnosed at an advanced stage with metastasis, missing the opportunity for radical surge...
10
DOI 10.1097/cad.0000000000001839
Open DOI
Capecitabine-induced pneumonitis: a rare case report and literature review
Capecitabine is an oral fluoropyrimidine prodrug widely used in the treatment of various malignancies, including colorectal cancer. While it is generally well-tolerated, rare and life-threatening toxicities can occur. Pneumonitis is an e...
Bibliographical & Catalog Notes
Title from cover.
Also issued online.
Vol. 1, no. 1 (OCT 1990)19911202 Notice published Printed on acid-free paper that meets the full ANSI standard for Permanent Paper